D-dimer to Determine Intensity of Anticoagulation to Reduce Clinical Outcomes in Patients With Atrial Fibrillation

Trial Profile

D-dimer to Determine Intensity of Anticoagulation to Reduce Clinical Outcomes in Patients With Atrial Fibrillation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Aug 2017

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Warfarin
  • Indications Atrial fibrillation
  • Focus Adverse reactions
  • Acronyms DATA-AF
  • Most Recent Events

    • 29 Aug 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top